A Look At Elevance Health (ELV) Valuation After CMS Plans Medicare Advantage Sanctions

Elevance Health (ELV) is under pressure after disclosing that the Centers for Medicare & Medicaid Services plans sanctions that would halt new enrollment and restrict communications in its Medicare Advantage Prescription Drug plans.

See our latest analysis for Elevance Health.

The CMS sanctions update comes after a tough stretch for the stock, with a 7 day share price return of 9.49% and a 30 day share price return of 14.56%. These moves contributed to an 18.24% year to date share price decline and a 27.89% 1 year total shareholder return decline, which suggests sentiment has weakened despite institutional buying, insider purchases and recent community focused initiatives.

If regulatory risk around Elevance’s Medicare business has you reassessing healthcare exposure, this could be a good moment to look at 32 healthcare AI stocks for fresh ideas in the sector.

With Elevance Health trading at $289.64 and screens flagging a wide gap to some valuation estimates, the key question is whether regulatory risk and weaker recent returns create an overlooked entry point or if the market is already discounting future growth.

Most Popular Narrative: 25.8% Undervalued

With Elevance Health last closing at $289.64 against a narrative fair value of $390.54, the gap is wide enough to raise questions about what the market might be missing according to NateF.

Elevance Health is navigating a complex environment with challenges in its Medicaid segment affecting short-term performance. While there are risks from Medicaid enrollment declines and increased competition, its established market presence and focus on integrated care position it as a potentially strong investment in the evolving healthcare space.

Read the complete narrative.

Curious how that valuation gets built. The narrative focuses on Medicare Advantage, value based care and digital health, along with a profitability path that assumes gradual margin repair.

Result: Fair Value of $390.54 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, that story can break if Medicaid pressures deepen further or if rising medical costs keep margins tight for longer than this narrative assumes.

Find out about the key risks to this Elevance Health narrative.

Next Steps

If this all feels mixed to you, that is the point. The story is not one sided and the data is there for you to weigh up. To see which positives others are focusing on, take a closer look at 5 key rewards.

Looking for more investment ideas?

If this Elevance update has you rethinking your watchlist, use this moment to refresh your research and line up a few new ideas worth tracking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com